Travere Therapeutics (NASDAQ:TVTX - Get Free Report) was upgraded by Zacks Research from a "strong sell" rating to a "hold" rating in a research report issued on Wednesday, Zacks reports.
Other equities analysts also recently issued research reports about the company. Weiss Ratings restated a "sell (e+)" rating on shares of Travere Therapeutics in a research report on Friday, September 18th. Guggenheim lowered their price target on Travere Therapeutics from $89.00 to $78.00 and set a "buy" rating on the stock in a research report on Wednesday, November 4th. Leerink Partners dropped their price objective on Travere Therapeutics from $78.00 to $67.00 and set an "outperform" rating for the company in a research note on Thursday, November 5th. Canaccord Genuity Group lifted their price objective on Travere Therapeutics from $70.00 to $72.00 and gave the company a "buy" rating in a report on Wednesday, November 4th. Finally, HC Wainwright restated a "buy" rating and issued a $67.00 target price on shares of Travere Therapeutics in a research note on Tuesday, September 22nd. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $72.55.
Check Out Our Latest Stock Report on Travere Therapeutics
Travere Therapeutics Trading Down 3.9%
Shares of Travere Therapeutics stock opened at $48.30 on Wednesday. The firm has a market capitalization of $4.64 billion, a PE ratio of -37.44 and a beta of 1.11. The company has a debt-to-equity ratio of 26.72, a current ratio of 3.00 and a quick ratio of 2.95. The company's fifty day moving average price is $54.62 and its two-hundred day moving average price is $47.92. Travere Therapeutics has a 52-week low of $22.59 and a 52-week high of $68.73.
Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.49). Travere Therapeutics had a negative return on equity of 185.69% and a negative net margin of 18.66%. The business had revenue of $224.56 million for the quarter, compared to the consensus estimate of $195.29 million. During the same period in the previous year, the business posted $0.28 earnings per share. Travere Therapeutics's revenue was up 36.2% on a year-over-year basis. On average, analysts expect that Travere Therapeutics will post -0.90 EPS for the current year.
Insider Buying and Selling
In related news, EVP Jula Inrig sold 44,674 shares of the company's stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $62.34, for a total transaction of $2,784,977.16. Following the transaction, the executive vice president owned 100,491 shares in the company, valued at $6,264,608.94. This represents a 30.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Peter Heerma sold 172,717 shares of the stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $63.43, for a total transaction of $10,955,439.31. Following the sale, the executive vice president directly owned 117,066 shares in the company, valued at approximately $7,425,496.38. This represents a 59.60% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 1,294,029 shares of company stock valued at $79,454,261. Insiders own 4.44% of the company's stock.
Hedge Funds Weigh In On Travere Therapeutics
A number of large investors have recently modified their holdings of the stock. GAMMA Investing LLC increased its holdings in shares of Travere Therapeutics by 53.4% in the second quarter. GAMMA Investing LLC now owns 606 shares of the company's stock valued at $34,000 after purchasing an additional 211 shares in the last quarter. Eurizon Capital SGR S.p.A. bought a new position in Travere Therapeutics in the 3rd quarter worth approximately $37,000. Corient Private Wealth LP lifted its holdings in Travere Therapeutics by 1.4% during the 2nd quarter. Corient Private Wealth LP now owns 48,125 shares of the company's stock worth $2,734,000 after buying an additional 648 shares in the last quarter. Allworth Financial LP lifted its holdings in Travere Therapeutics by 98.7% during the 3rd quarter. Allworth Financial LP now owns 1,657 shares of the company's stock worth $94,000 after buying an additional 823 shares in the last quarter. Finally, Swiss National Bank boosted its position in Travere Therapeutics by 0.6% in the 1st quarter. Swiss National Bank now owns 168,100 shares of the company's stock valued at $4,994,000 after buying an additional 1,000 shares during the last quarter.
Travere Therapeutics Company Profile
(
Get Free Report)
Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with an emphasis on kidney and metabolic disorders. The company was formerly known as Retrophin and adopted the Travere Therapeutics name in 2020. Its commercial products include FILSPARI (sparsentan), an oral treatment approved in the United States for adults with primary IgA nephropathy at risk of disease progression, and THIOLA EC (tiopronin), used to help prevent cystine kidney stones in people with cystinuria.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Travere Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Travere Therapeutics wasn't on the list.
While Travere Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.